Navigation Links
Pooled-Analysis of 54 Clinical Studies Shows No Increased Risk of Heart Attack With Abacavir Therapy
Date:8/6/2008

n allergic reaction before. If your healthcare professional tells you that you can take ZIAGEN again, start taking it when you are around medical help or people who can call a doctor if you need one.

A build up of lactic acid in the blood and an enlarged liver, including fatal cases, have been reported.

Do not take ZIAGEN if your liver does not function normally.

Worsening of liver disease (sometimes resulting in death) has occurred in patients infected with both HIV and hepatitis C virus who are taking anti-HIV medicines and are also being treated for hepatitis C with interferon with or without ribavirin. If you are taking ZIAGEN as well as interferon with or without ribavirin and you experience side effects, be sure to tell your doctor.

When you start taking HIV medicines, your immune system may get stronger and could begin to fight infections that have been hidden in your body, such as pneumonia, herpes virus, or tuberculosis. If you have new symptoms after starting your HIV medicines, be sure to tell your doctor.

Changes in body fat may occur in some patients taking antiretroviral therapy. These changes may include an increased amount of fat in the upper back and neck ("buffalo hump"), breast, and around the trunk. Loss of fat from the legs, arms, and face may also occur. The cause and long-term health effects of these conditions are not known at this time.

Some HIV medicines including ZIAGEN may increase your risk of heart attack. If you have heart problems, smoke, or suffer from diseases that increase your risk of heart disease such as high blood pressure, high cholesterol, or diabetes, tell your doctor.

The most common side effects of ZIAGEN include nausea, vomiting, tiredness, headache, diarrhea, trouble sleeping, fever and chills, and loss of appetite. Most of these side effects did not cause people to stop taking ZIAGEN.

For additional important information about ZIAGEN please visit

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2008)...e-USNewswire/ -- Abnormalities in auditory and lan... autism spectrum disorder by using magnetoencephal...y at the annual meeting of the Radiological Societ...we can record the tiny magnetic fields associated ...rts, Ph.D., vice chair of research in the Departme...
(Date:11/28/2008)...ewswire-FirstCall/ -- Eli Lilly and Company,(NYSE...Application (sNDA) from,the U.S. Food and Drug Ad...),for the management of chronic pain. Lilly plans... 2009, adding data from a recently completed posit...nee. , The decision does not affect duloxet...
(Date:11/26/2008)... Children whose eyes are... increased risk of developing mental illness by ea...inic study published this month in Pediatrics , th...atrics. , , The retrospective study examine...mus (misaligned eyes) and compared them with recor...
(Date:11/26/2008)...ects , , FRANKLIN, Mass., Nov. 26 /PRNewswi...ard: PLCSF) announced today that it has received f...ation (FDA) for its U.S. pivotal trial to study th...(TM) and associated therapy in the prevention of ... FDA also approved PLC,s request to expand their i...
Breaking Medicine Technology:Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Eye Divergence in Children Triples Risk of Mental Illness 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Possible biological explanation for C Section linked allergies and asthma found 19976 1Possible biological explanation for C Section linked allergies and asthma found 19976 2Crdentia Announces 2008 First Quarter Results 19972 1Crdentia Announces 2008 First Quarter Results 19972 2Crdentia Announces 2008 First Quarter Results 19972 3Crdentia Announces 2008 First Quarter Results 19972 4Crdentia Announces 2008 First Quarter Results 19972 5Crdentia Announces 2008 First Quarter Results 19972 6Crdentia Announces 2008 First Quarter Results 19972 7FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 1FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 2FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 3FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 4Iraq war service 3A A risk factor for bronchiolitis 3F 19967 1Iraq war service 3A A risk factor for bronchiolitis 3F 19967 2
..., FL -- (MARKET WIRE) -- July 06, 2007 -- DOR BioP...://studio.financialcontent.com/Engine?Account=iwir...p://studio.financialcontent.com/Engine?Account=iwi...R" or the "Company") announced today that the Euro...7 B1, with claims related to,oral vaccination usin...
...ublished in The Lancet on TMC125, an Investigation... /PRNewswire/ -- Data from two,ongoing Phase 3 stu... HIV-1 adult patients with documented non-nucleosi...tease inhibitor (PI),resistance reached an undetec...ndetectable level < 50 HIV-1 RNA copies/mL) with,T...
Other Medicine Technology:DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 2DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 3DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 4DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 5DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 6TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 2TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 3TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 4
(Date:12/1/2008)... 1 This December, Anthem Blue,Cro...he Anthem Blue Cross,HealthFair Bus travels the s...,on Monday, December 1 from the Anthem offices in ...n a multi-city tour to include Los Angeles, Ventur...isco (see detailed schedule,below). , (Pho...
(Date:12/1/2008)...PRNewswire/ -- Question. What would happen if,we ...lding exercise? The,fitness world would certainly...rship fees would have to close. 2. Phony exercise ...t. 3. We would never have to spend another dime on...,s take-home pay is now estimated at 35 billion,d...
(Date:12/1/2008)...D Global Telemedicine, Inc. deploys telemedicine d...t program. 17 school sites in Sevier County, Tenne..., North Chelmsford, MA (PR...dicine & Cherokee Health Systems collaborated ...s in Sevier County, Tennessee. In addition to thi...
(Date:12/1/2008)...stage breast cancer who have undergone breast augm...l-breast radiation treatment called brachytherapy,...l meeting of the Radiological Society of North Ame...ave better cosmetic outcomes and avoid the risk of...ndergo whole-breast radiation therapy. , "We are...
Breaking Medicine News(10 mins):Health News:Anthem Blue Cross Gives the Gift of Health to California 2Health News:Anthem Blue Cross Gives the Gift of Health to California 3Health News:Push-Ups: 'It's Horizontal Jogging' 2Health News:Telemedicine Becoming More Relevant to Children's Health Within School Systems. 2Health News:Telemedicine Becoming More Relevant to Children's Health Within School Systems. 3Health News:Breast cancer treatment offers better outcome to women with implants 2
...2006 issue of General Dentistry, the AGD’s clinica...especially that of the tongue is harmful and shoul...e, the report describes the condition of a young g...was massive scar tissue formation around the area ...
... milk substitute, and a highly vulnerable commodit...ealth concerns determine what goes into formula mi.../ The Codex Alimentarius Commission, part of bot...of the United Nations and the World Health Organis...
...ched a $38 million project along with major region...u threat in Asia and the Pacific. // The Manila-b...e resources urgently needed to help control and re...us, and to increase the region's preparedness for ...
...ons (ASPS) reports say that plastic surgery was pe... The ethnic community opts for this surgery than ...nce their appearance or minimize the signs of agin...nd more people opted for it in the year 2005 with ...
Other Medicine News:
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
Medicine Products: